Successful Treatment with Alectinib for Choroidal Metastasis in Anaplastic Lymphoma Kinase Rearranged Non-small Cell Lung Cancer

Choroidal metastasis is rare in cancer patients and it may cause visual disturbances that reduce their quality of life. In non-small cell lung cancer (NSCLC), targeted therapy against actionable driver mutations has gradually replaced radiotherapy as the treatment of choice for choroidal metastasis....

Descripción completa

Detalles Bibliográficos
Autores principales: Funazo, Tomoko, Morita, Kyohei, Ikegami, Naoya, Konishi, Chisato, Nakao, Satoshi, Ariyasu, Ryo, Taki, Masato, Nakagawa, Kazuhiko, Hwang, Moon Hee, Yoshimura, Chie, Wakayama, Toshiaki, Nishizaka, Yasuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5635306/
https://www.ncbi.nlm.nih.gov/pubmed/28794371
http://dx.doi.org/10.2169/internalmedicine.8488-16
Descripción
Sumario:Choroidal metastasis is rare in cancer patients and it may cause visual disturbances that reduce their quality of life. In non-small cell lung cancer (NSCLC), targeted therapy against actionable driver mutations has gradually replaced radiotherapy as the treatment of choice for choroidal metastasis. Recently, there have been several case reports of choroidal metastasis in patients with anaplastic lymphoma kinase (ALK)-rearranged NSCLC. We herein report the case of a 40-year-old Japanese woman diagnosed with choroidal metastasis of an ALK-rearranged NSCLC who received alectinib as the first-line chemotherapy. Alectinib may be the best treatment for choroidal metastasis in patients harboring an ALK translocation because of its favorable side effect profile involving visual disturbances.

Ejemplares similares